Upgrade to SI Premium - Free Trial

Barclays Upgrades GlaxoSmithKline (GSK) to Overweight

October 23, 2014 8:07 AM

Barclays upgraded GlaxoSmithKline (NYSE: GSK) from Equalweight to Overweight.

For an analyst ratings summary and ratings history on GlaxoSmithKline click here. For more ratings news on GlaxoSmithKline click here.

Shares of GlaxoSmithKline closed at $44.41 yesterday.

Categories

Upgrades

Next Articles